MedPath

Precigen

Precigen logo
🇺🇸United States
Ownership
Public
Established
1998-01-01
Employees
202
Market Cap
$330.8M
Website
http://www.precigen.com
Introduction

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

easternprogress.com
·

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Precigen, Inc. announced that its President and CEO, Helen Sabzevari, will participate in a fireside chat on September 18, 2024, from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference in New York.
morningstar.com
·

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen reports Q3 2024 financial results and business updates, including completion of pre-BLA meeting with FDA for PRGN-2012, commercial and manufacturing readiness for potential 2025 launch, initiation of confirmatory clinical trial for PRGN-2012, and preparation for end of Phase 1b meeting with FDA for PRGN-3006 in AML. Preclinical data for PRGN-3008 presented at SITC 2024 showcasing potential as best-in-class CD19-targeting CAR-T treatment.

Behind the Breakthroughs: How to Turn $1000000 CAR Ts into “Real” Medicines

Helen Sabzevari discusses barriers to cell and gene therapies, emphasizing high costs and limited accessibility, and introduces Precigen's innovations to make CAR Ts more cost-effective and safer, including in-body manufacturing and safety switches.
biospace.com
·

Cell And Gene Therapy Clinical Trials Market Size to Hit USD 47.40 Bn by 2033

The global cell and gene therapy clinical trials market was valued at USD 11.62 billion in 2023 and is projected to reach USD 47.40 billion by 2033, growing at a CAGR of 15.09%. Factors driving growth include a favorable regulatory environment, increasing interest in cancer treatments, patient demand for innovative therapies, and rising R&D funding. North America leads with a 49.76% share, while Asia Pacific is expected to grow fastest at a CAGR of 15.7%. The oncology segment dominates with a 49.1% share.
finance.yahoo.com
·

7 High-Potential Penny Stocks in the Biotech Sector

Sana's hypoimmune technology reversed diabetes in mice without immunosuppression. Precigen's UltraCAR-T showed anti-tumor efficacy. Atossa's Phase 2 trial for breast cancer treatment authorized. BioLine RX's APHEXDA NDA accepted by FDA. Corvus's CPI-818 shows promise for T cell lymphoma. Ardelyx resubmitted NDA for XPHOZAH.
© Copyright 2025. All Rights Reserved by MedPath